Our results are in accordance with recent studies using RT combined with mAb-mediated blockade of PD-1 or PD-L1 in mouse models of melanoma (Sharabi et al., 2015), breast carcinoma (Deng et al., 2014, Sharabi et al., 2015), colon adenocarcinoma (Deng et al., 2014), glioma (Zeng et al., 2013) and multiple myeloma (Jing et al., 2015). Here, PDCD1 is linked to melanoma.